Table 1.
Baseline characteristics of patients treated with tildrakizumab by week 28 PASI groups
| Week‐28 PASI groups: tildrakizumab 100 mg (n = 575) | Week‐28 PASI groups: tildrakizumab 200 mg (n = 581) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PASI < 50 | PASI 50–74 | PASI 75–89 | PASI 90–99 | PASI 100 | PASI < 50 | PASI 50–74 | PASI 75–89 | PASI 90–99 | PASI 100 | |
| Number of patients | 48 | 82 | 137 | 175 | 133 | 23 | 105 | 114 | 169 | 170 |
| Age, years, mean (SD) | 49.2 (13.8) | 46.9 (12.9) | 46.5 (13.1) | 45.7 (13.3) | 42.6 (13.3) | 47.2 (15.2) | 47.2 (13.1) | 46.3 (12.1) | 46.1 (13.6) | 44.4 (13.7) |
| Male (%) | 81.3 | 70.7 | 68.6 | 67.4 | 68.4 | 87.0 | 67.6 | 64.9 | 76.3 | 76.5 |
| Race (%) | ||||||||||
| White | 83.3 | 73.2 | 84.7 | 81.7 | 82.0 | 82.6 | 75.2 | 73.7 | 83.4 | 81.2 |
| Black | 0.0 | 0.0 | 3.7 | 2.3 | 2.3 | 0.0 | 2.9 | 3.5 | 2.4 | 1.8 |
| Asian | 10.4 | 25.6 | 9.5 | 14.3 | 7.5 | 17.4 | 21.9 | 19.3 | 12.4 | 12.4 |
| Others | 6.3 | 1.2 | 2.2 | 1.7 | 8.3 | 0.0 | 0.0 | 3.5 | 1.8 | 4.7 |
| Bodyweight (kg), mean (SD) | 99.5 (25.5) | 84.4 (22.6) | 94.3 (24.3) | 87.3 (23.1) | 86.4 (20.1) | 93.3 (16.9) | 89.9 (24.1) | 89.2 (22.4) | 90.2 (23.1) | 85.0 (21.6) |
| Body mass index (kg/m2), mean (SD) | 32.0 (6.4) | 29.0 (7.3) | 31.8 (7.6) | 29.4 (7.2) | 29.3 (6.3) | 31.3 (9) | 29.9 (6.6) | 30.7 (7.7) | 30.2 (7.9) | 28.3 (6.9) |
| % body surface area affected, mean (SD) | 34.3 (16.9) | 35.7 (20.1) | 30.7 (17.5) | 33.2 (19.2) | 27.3 (15.1) | 33.5 (18) | 32.7 (19.2) | 31.6 (18.7) | 30.8 (16.9) | 30.2 (16.4) |
| Years of psoriasis, mean (SD) | 22.8 (15.5) | 18.6 (14.9) | 18.3 (13.6) | 16.5 (11.9) | 13.8 (10.6) | 17.8 (12.5) | 17.5 (11.5) | 18.1 (12) | 17.7 (13) | 15.7 (11.6) |
| PASI, mean (SD) | 20.2 (6.4) | 21.8 (9.7) | 20.1 (7.8) | 21 (8.3) | 17.9 (5.4) | 19.1 (7.6) | 20 (8.8) | 20.3 (9.1) | 20.6 (7.5) | 19.9 (7.6) |
| DLQI total score, mean (SD) | 13.9 (7.0) | 13.6 (7.3) | 13.8 (6.8) | 15.0 (7.0) | 14.4 (7.0) | 12.7 (5) | 13 (6.8) | 13 (7.3) | 13.1 (7.0) | 13.7 (7.0) |
| Previous medical conditions (%) | ||||||||||
| Psoriatic arthritis | 14.6 | 17.1 | 15.3 | 16.0 | 18.1 | 26.1 | 22.9 | 11.4 | 16.0 | 12.9 |
| Cardiovascular diseases | 37.5 | 31.7 | 29.2 | 22.9 | 21.8 | 39.1 | 29.5 | 28.1 | 31.4 | 19.4 |
| Diabetes | 14.6 | 7.3 | 11.0 | 8.6 | 7.5 | 13.0 | 14.3 | 13.2 | 11.8 | 8.2 |
| Previously treated with biologics (%) | 31.3 | 15.9 | 16.1 | 18.9 | 12.8 | 26.1 | 17.1 | 18.4 | 14.8 | 17.1 |
DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation.